JUN 20, 2019 10:16 AM PDT

Sickle cell drug promising in clinical trial

WRITTEN BY: Nouran Amin

UConn School of Medicine researchers report that an investigational drug used for treating for the sickle cell disease has shown promising results in early clinical trials. Specifically, the experimental drug IMR-687 was shown to reduce two impact factors— sickling of red blood cells and blood vessel blockages. These factors result in debilitating pain, organ damage and early patient mortality.

Learn more on sickle cell disease, also known as sickle cell anemia:

“After 13 weeks of testing in its current clinical trial, the orally administered, once-a-day phosphodiesterase 9 (PDE9) inhibitor in adult patients with sickle cell disease is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease,” says Dr. Biree Andemariam, lead investigator for the clinical trial, associate professor of medicine at UConn School of Medicine and director of the New England Sickle Cell Institute at UConn Health. "These initial Phase 2a data demonstrate the potential of IMR-687 to significantly impact key biomarkers associated with the pathology of this serious disease.”

The drug has been granted U.S. Orphan Drug Designation, U.S. Rare Pediatric Designation, and Fast Track Designation by the Food and Drug Administration (FDA).

University of Connecticut: In sickle cell disease, a patient's red blood cells are abnormally sickle – or crescent – shaped, which can lead to painful blood vessel blockages. (Getty Images)

"We are encouraged by this interim Phase 2a analysis that reinforces our belief in the potential of IMR-687 as a single oral, once-a-day therapeutic," said Rahul D. Ballal, chief executive officer of Imara. "IMR-687 uniquely targets both red cell and white cell aspects of the disease, and we are working to expeditiously advance this novel therapy through clinical development, with a goal of delivering it to patients with SCD who are in need of innovative treatment options."

"The interim Phase 2a data reflect trends that could be indicative of meaningful clinical translation of these important measures in sickle cell disease," Andemariam adds.

Source: University of Connecticut

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 19, 2020
Drug Discovery & Development
MAY 19, 2020
Can Chinese Drug Cure COVID-19 Without Vaccine?
Researchers at China’s Peking University have announced that they are developing a treatment capable of blocking C ...
JUN 05, 2020
Drug Discovery & Development
JUN 05, 2020
Biofriendly Drug Design for Neurological Diseases
Carbon quantum dots are a class of nanoparticles that can be placed to good use for treating neurodegenerative diseases ...
JUN 10, 2020
Drug Discovery & Development
JUN 10, 2020
Does Your Gut Microbiota Alter Drug Activity?
Scientists have created a systematic way to evaluate how the microbial community in our gut influences drug behavior. Fi ...
JUN 23, 2020
Drug Discovery & Development
JUN 23, 2020
Psychedelic DMT to Enter Clinical Trials
Neuro-pharmaceutical company, MindMed, has announced that it will begin a double-blind placebo-controlled Phase 1 clinic ...
JUN 23, 2020
Drug Discovery & Development
JUN 23, 2020
FDA Warns Against Toxic Hand Sanitizers
The COVID-19 pandemic has seen demand for hand sanitizers soar in recent months. As such, the Food and Drug Administrati ...
JUN 25, 2020
Cannabis Sciences
JUN 25, 2020
Can CBD Oil Treat Eczema?
Around 30% of Americans are affected by eczema, a common condition known to cause dry skin, itching, irritation, and inf ...
Loading Comments...